Prostate cancer Prostate malignancy
Conditions
Interventions
None listed
Sponsors
Urologie
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: - Signed written informed consent - Patients with clinically intermediate to high-risk localized PCa, who are planned for radical prostatectomy (i.e. Gleason score *3+4
Exclusion criteria
Exclusion criteria: - Patients who are unwilling or unable to sign written informed consent - Patients who meet exclusion criteria for MRI following the protocol of the radiology department of the UMC Utrecht (see Appendix I for the 7T-MRI questionnaire). - Patients with previous treatment for PCa. - Patients with a history of radiotherapy to the pelvis. - Patients who underwent a transurethral resection of the prostate (TURP) or stenting of the prostate
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| * To assess the prediction of tumour localisation, extraprostatic extension, metabolism and GS of 7T-MRI for PCa, based on whole-mount histopathology validation after radical prostatectomy. * To assess the prediction of tumour aggressiveness and detection of metastasis, of 68Ga-PSMA-PET/CT for PCa, based on the SUVmax and SUVmean, compared to whole-mount histopathology validation after radical prostatectomy. | — |
Secondary
| Measure | Time frame |
|---|---|
| * To find metabolic markers to predict/mirror PCa Gleason Score, and to create a Gleason score prediction tool for steering individualized treatment options in future studies. * To compare radiological results from 3T-MRI with 7T-MRI for the detection of PCa, GS and EPE. * To assess the ability of 7T-MRI to diagnose extraprostatic extension, by evaluating a threshold value of length of capsular contact of dominant lesions and comparing to whole-mount histopathology validation after radical prostatectomy. | — |
Countries
Netherlands
Outcome results
None listed